A Phase 2 interventional study of TQC2731 injection and TQC2731 Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.. Active, not recruiting at 60 sites in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-12.
Sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited — 2 open to participants now, 6 under way, 2 of them phase 3. Pulmonary Disease, Chronic Obstructive · Sino Biopharmaceutical Limited.
Among the 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited, this one is the 3rd largest by enrollment, is one of 6 that started in 2024, is one of 8 in phase 2, and was the 10th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 40–80
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 40–80
By country, each count listing its studies:
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 6 started in 2024.
This study's enrollment of 258 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 113 across the 17 interventional studies. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., one of the names counted as Sino Biopharmaceutical Limited. Under that name alone:
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. is the lead sponsor of 18 studies on the registry; 14 are open to participants now.
4 of the studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07464587Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease | 2027-02 |
| NCT07147946Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease | 2027-03 |
| NCT06707883Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease | 2026-12 |
| NCT06789289Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.A Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease | 2027-03-17 |
Add all 4 to your calendar (.ics) → With an account.
Among the 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy and safety of TQC2731 injection in patients with moderate to severe chronic obstructive pulmonary disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TQC2731 injection, 28days as a treatment cycle.
Drug: TQC2731 injection
TQC2731 Placebo, 28days as a treatment cycle.
Drug: TQC2731 Placebo
TQC2731 injection is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP)
TQC2731 Placebo without drug substance.
Annual rate of acute COPD exacerbation
Annualized rate of moderate or severe COPD exacerbations over the 24-week treatment period compared to placebo
Time frame: Baseline to week 24
Change in pre-bronchodilator forced expiratory volume (FEV1)
Change in pre-bronchodilator FEV1 from baseline to week 24 compared to placebo.
Time frame: Baseline to week 24
Annual rate of acute COPD exacerbation
Annualized rate of moderate COPD exacerbations over the 52-week treatment period compared to placebo.
Time frame: Baseline to week 52
Improvement in St. George's Respiratory Questionnaire (SGRQ)
Proportion of patients with SGRQ improvement ≥4 points at Week 52
Time frame: Baseline to week 52
Change in SGRQ
Change from baseline to Week 52 in SGRQ total score compared to placebo
Time frame: Baseline to week 52
Change in pre-bronchodilator FEV1
Change in pre-bronchodilator FEV1 from baseline to week 52 compared to placebo.
Time frame: Baseline to week 52
Annual rate of acute COPD exacerbation
Annualized rate of severe COPD exacerbations over the 52-week treatment period compared to placebo.
Time frame: Baseline to week 52
Change in post-bronchodilator FEV1
Change in post-bronchodilator FEV1 from baseline to week 24 and 52 compared to placebo.
Time frame: Baseline to week 24 and 52
Change in EXACT
Change from baseline to Week 52 in EXACT total score compared to placebo.
Time frame: Baseline to week 52
Adverse Events (AE) and Serious Adverse Events (SAE)
The incidence and severity of AE and SAE, as well as abnormal laboratory examination index.
Time frame: Baseline to 64 weeks
Anti-drug antibodies (ADA)
Incidence of ADA.
Time frame: Baseline through week 52
Immunoglobulin E (IgE)
Changes in IgE levels in peripheral blood.
Time frame: Baseline to 52 weeks
Fractional exhaled nitric oxide (FeNO)
Changes in FeNO.
Time frame: Baseline to 52 weeks
Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.
Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's planned 24 months is above that.
Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TQC2731
Pulmonary Disease, Chronic Obstructive →
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. →